REGN698.25-2.05%
REGN · US
1y range: 686.36 → 790.81 · as of 2026-05-15
Next earnings
2026-07-30
in 72d
Recent material news
- Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda2026-05-18T12:28
- Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas2026-05-18T07:01
- Regeneron Pharmaceuticals Provides Update on Phase 3 Trial of Fianlimab Combination in First-Line Unresectable or Metastatic Melanoma2026-05-16T08:51
- Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial2026-05-05T07:00
- Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?2026-05-02T15:20
Want this depth on every stock you watch?
ThickerPeek writes a daily AI digest on 165+ stocks, weekly theses, earnings briefings, and alerts — for €19/mo. Free tier available.
Not investment advice. ThickerPeek is a research tool. AI-written content is informational, not a buy/sell recommendation. Investment decisions are your own responsibility.